Tapan M. Kadia
University of Texas MD Anderson Cancer Center
1035 Papers
2.3K Citations
Tapan M. Kadia is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 52, co-authored 700 publications. Previous affiliations of Tapan M. Kadia include University of Perugia & University of Texas Health Science Center at Houston.
Chat about Author
Papers
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Mahran Shoukier,Hagop M. Kantarjian,Jorge E. Cortes,Elias Jabbour,Farhad Ravandi,Guillermo Garcia-Manero,Tapan M. Kadia,Jairo Matthews,Srdan Verstovsek,Gautam Borthakur +9 more
TL;DR: A small number of patients with CML may develop grade ≥3 thrombocytopenia, and TKIs are standard therapy for chronic phase (CP) chronic myeloid leukemia (CML).
6
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial
Koji Sasaki,Hagop M. Kantarjian,Farhad Ravandi,Nicholas J. Short,Partow Kebriaei,Xuelin Huang,Nitin Jain,Marina Konopleva,Guillermo Garcia-Manero,Richard E. Champlin,Tapan M. Kadia,Koichi Takahashi,Naval Daver,Hind Rafei,Joseph D. Khoury,Jeffrey L. Jorgensen,Sa A. Wang,Maria Khouri,Jovitta Jacob,Rebecca Garris,Susan O'Brien,Elias Jabbour +21 more
TL;DR: The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy showed encouraging results in this patient population, and the sequential addition of blinatumomab might optimize the efficacy of the regimen, reduce its toxicities, and further improve outcomes in R-R ALL.
6
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Bachar Samra,Hagop M. Kantarjian,Koji Sasaki,Marina Konopleva,Rita Khouri,Susan O'Brien,Alessandra Ferrajoli,Cesar Nunez,Tapan M. Kadia,Elias Jabbour +9 more
TL;DR: In this article, the authors reviewed outcome of pts with Ph+ ALL treated with chemotherapy + TKI without allogeneic stem cell transplant (ASCT) who later discontinued TKI mainly due to adverse events, and analyzed their characteristics and outcomes including molecular relapse rates and treatment-free remission (TFR).
6
Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
Elias Jabbour,Hagop M. Kantarjian,Deborah A. Thomas,Farhad Ravandi,Jorge E. Cortes,Stefan Faderl,Naveen Pemmaraju,Tapan M. Kadia,Rebecca Garris,Guillermo Garcia-Manero,Gautam Borthakur,William G. Wierda,Susan O'Brien +12 more
TL;DR: Combination of chemotherapy (CTX) with TKI is effective in the treatment of Ph+ ALL and ponatinib is a more potent BCR-ABL inhibitor, which may be associated with better outcome.
6
Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)
Preetesh Jain,Hagop M. Kantarjian,Deborah A. Thomas,Farhad Ravandi,Tapan M. Kadia,Jan A. Burger,Gautam Borthakur,Jorge E. Cortes,Naval Daver,Elias Jabbour,Charles Koller,Marina Konopleva,Naveen Pemmaraju,Marry A Kelly,Rebecca Garris,Susan O'Brien,Stefan Faderl +16 more
TL;DR: Three patients with Ph+ALL underwent alloSCT without MMR without MMR who obtained CMR with 2nd generation TKIs showed a prompt response to 2-TKIs treatment that can rescue Ph+ ALL patients after SCT failure.
5